Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.

about

Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.

Item

http://www.wikidata.org/entity/Q38707629

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Comparison of biosimilar filgr ...... atients with multiple myeloma.

@en

type

Item

label

Comparison of biosimilar filgr ...... atients with multiple myeloma.

@en

prefLabel

Comparison of biosimilar filgr ...... atients with multiple myeloma.

@en

P1476

Comparison of biosimilar filgr ...... atients with multiple myeloma.

@en

P2093

Anita Schmitt

http://www.w3.org/2001/XMLSchema#string

Anthony D Ho

http://www.w3.org/2001/XMLSchema#string

Jens Hillengass

http://www.w3.org/2001/XMLSchema#string

Katharina Lisenko

http://www.w3.org/2001/XMLSchema#string

Marc-Andrea Baertsch

http://www.w3.org/2001/XMLSchema#string

Mark Kriegsmann

http://www.w3.org/2001/XMLSchema#string

Mathias Witzens-Harig

http://www.w3.org/2001/XMLSchema#string

Patrick Wuchter

http://www.w3.org/2001/XMLSchema#string

Petra Pavel

http://www.w3.org/2001/XMLSchema#string

Renate Meiser

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.

Clinical development of biosimilars: an evolving landscape.

Clinical experience with Zarzio® in Europe: what have we learned?

Hematopoietic stem cell transplantation activity in Europe.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.

P31

scholarly article

P356

10.1111/TRF.14211

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28653421

http://www.w3.org/2001/XMLSchema#string